EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 April 2025
EMA/CVMP/102998/2025
Committee for Veterinary Medicinal Products

Summary of opinion[1] (initial authorisation)

Emevet

International non-proprietary name (INN): Maropitant

On 10 April 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a marketing authorisation for the veterinary medicinal product Emevet, chewable tablet, intended for dog. The applicant for this veterinary medicinal product is CP-Pharma Handelsgesellschaft mbH.

Emevet is an anti-emetic medicinal product containing Maropitant (ATCvet code QA04 AD90) as active substance. Maropitant is a neurokinin-1 (NK1) receptor antagonist, which acts in the central nervous system by inhibiting Substance P, the key neurotransmitter involved in vomiting.

The benefits of Emevet are

- Prevention of nausea induced by chemotherapy in dogs.
- Prevention of vomiting induced by motion sickness in dogs.
- Prevention and treatment of vomiting, in conjunction with maropitant solution for injection and in combination with other supportive measures in dogs.

The most common side effects are vomiting and in very rare cases lethargy and neurological disorders.

Emevet is a generic of Cerenia, which has been authorised in the EU since 29 September 2006. Studies have demonstrated the satisfactory quality of Emevet, and its bioequivalence to the reference product Cerenia.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Emevet and therefore recommends the granting of the marketing

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

authorisation.